奥德金联合奥扎格雷治疗老年脑梗死的临床疗效及机制

Clinical Efficacy and Mechanism of Adegold Combine with Ozagrel in Elderly Patients with Cerebral Infarction

目的:研究奥德金联合奥扎格雷对脑梗死老年患者的临床疗效并探讨其治疗机制。方法:选择2014年11月到2016年7月我院收治的90例脑梗死老年患者,按随机数字表法分成对照组和试验组,各45例。对照组患者给予奥扎格雷治疗,试验组患者给予奥德金联合奥扎格雷治疗,两组患者均给予治疗14 d。评价并比较两组患者临床疗效。采用美国国立卫生院神经功能缺损量表(NIHSS)评分和简易精神状态评价量表(MMSE)评分评价两组患者治疗前后神经功能损伤情况。检测并比较两组患者治疗前后血清超敏C反应蛋白(hs-CRP)、S100B钙结合蛋白(S100B)、基质金属蛋白酶-8(MMP-8)及缺氧诱导因子-1α(HIF-1α)水平。记录并比较两组患者治疗过程中的不良反应发生情况。结果:试验组患者的总有效率为88.89%,明显高于对照组的68.89%(P<0.05)。治疗后,两组患者血清hs-CRP、S100B、MMP-8及HIF-1α水平均明显降低,且试验组患者降低更明显(P<0.05)。治疗后,试验组患者的NIHSS评分、MMSE评分均明显优于对照组(P<0.05)。治疗过程中,对比两组的不良反应发生率,差异无统计学意义(P>0.05)。结论:奥德金联合奥扎格雷能够明显改善老年脑梗死患者的神经功能损伤,降低血清hs-CRP、S100B、MMP-8及HIF-1α水平,临床疗效和安全性较好,值得在临床上推广应用。

Objective： To study the clinical efficacy and the mechanism of adegold combined with ozagrel in the treatment of elderly patients with cerebral infarction. Methods： A total of 90 elderly patients with cerebral infarction, who were treated in Tianjin Integrated Traditional Chinese and Western Medicine Hospital from November 2014 to July 2016, were enrolled in this study and randomly divided into control group（n=45） and treatment group（n=45）. The control group was treated with Ozagrel, while the treatment group was treated with adegold combined with Ozagrel. The two groups were treated for 14 days. The clinical efficacy of the two groups was evaluated and compared. The neurologic injury of the two groups before and after treatment was evaluated by the national institute of health stroke scale（NIHSS） and mini-mental state examination（MMSE）. The levels of serum high-sensitivity C-reactive protein（hs-CRP）, S100 calcium-binding protein B（S100 B）, matrix metalloproteinase-8（MMP-8） and hypoxia-inducible factor-1α（HIF-1α） in the two groups before and after treatment were detected and compared. The adverse reactions of the two groups were recorded and compared. Results： The total efficacy rate（88.89%） of the treatment group was significantly higher than that（68.89%） of the control group（P〈0.05）. After treatment, the levels of serum hs-CRP, S100 B, MMP-8 and HIF-1α in the two groups were significantly lower than before treatment, and those in the treatment group were much lower（P〈0.05）. After treatment, the NIHSS score and MMSE score of the experimental group were better than those of the control group（P〈0.05）. During the treatment, there was no significantly difference in the incidence of adverse reactions between the two groups（P〈0.05）. Conclusion： Adegold combined with Ozagrel in the treatment of elderly patients with cerebral infarction can significantly improve neurologic injury and reduce the levels of serum hs-CRP, S100 B, MMP-8 and HIF-1α, with good clinical efficacy and security, which is worthy of clinical application.